Add onc brain to your Home Screen: tap Share, then Add to Home Screen.
ARTO: first RCT signal MDT improves OS + PCSS in oligomet mCRPC; MDT/SBRT consistently delays progression across oligorecurrent HSPC.
EAU 2026 prostate: MDT/SBRT delays progression and defers systemic Tx consistently across STOMP, ORIOLE, WOLVERINE, RADIOSA, but guideline integration stays unresolved given heterogeneous endpoints and small N. ARTO is the first RCT to hint at OS + PCSS benefit in castration-resistant oligomets. Selection refinement via PSMA PET burden (PP3) is the key next step.
read the full digest →Studies · 73
- EAU 2026: MDT/SBRT Intensification in Oligometastatic Prostate Cancer (Fonteyne)review: MDT/SBRT delays progression and defers systemic Tx in oligomet HSPC; ARTO is the first RCT hinting at an OS benefit.
- NRG Oncology/RTOG 0848OS HR 0.96 (90% CI 0.79-1.18), p=0.77; adding adjuvant chemoradiation to gemcitabine did not improve survival after resected pancreatic head adenoca.
- RAPCHEM (BOOG 2010-03)10-yr LRR 2.9% overall with response-adapted RT de-escalation post-NAC; low across all risk strata.
- NRG Oncology RTOG 053910-yr PFS 85.2%, 72.2%, 42.5% for low/intermediate/high-risk WHO grade 1-3 meningioma at median ~12yr f/u.
- FIRESTORMDose-escalated postop RT: 5-yr PFS 65.8% vs 38.8%, MVA HR 0.40 (0.24-0.69) in high-risk meningioma.
- PrTK03 (aglatimagene besadenovec + EBRT)DFS HR 0.70 (0.52–0.94), p=0.016 favoring aglatimagene + valacyclovir + EBRT vs placebo in intermediate/high-risk localized prostate cancer.
- AREST3-yr LRFS 89.2% vs 80.9%, HR 0.52 (p=0.02) favoring adj RT in pT1-2 pN0 OSCC with intermediate-risk features; DFS/OS NS.
- mRCAT-IIIpCR 61% vs 29% (p<0.0001) with node-sparing SCRT + CAPOX + tislelizumab vs conventional SCRT + CAPOX in pMMR LARC.
- Breast RT + Systemic Therapy Concurrency Review (Speers)T-DXd ILD 9.6% vs T-DM1 1.6% (DESTINY-Breast05); ASCO26 PK-guided concurrency framework for breast RT + systemic agents.
- ES-SCLC Concurrent TRT + Chemoimmunotherapy (LBA8005)mOS 10.0 vs 11.8mo, HR 1.14, p=0.40: concurrent TRT adds no OS benefit to chemoIO in ES-SCLC.
- ctDNA surveillance in non-operative rectal cancer managementctDNA sensitivity only 41% for local regrowth vs 74% for distant mets in 110 NOM rectal pts; risk stratifies but cannot replace imaging.
- DeLLphi-304 (tarlatamab CNS outcomes)CNS PFS HR 0.54 (ITT), HR 0.40 in brain mets; CNS CR 14.9% vs 5.4% with tarlatamab vs chemo 2L SCLC.